Fulcrum doses first patient in Phase 1b of FTX-6058; cash $218.2M; appoints Kate Haviland as Chair

Fulcrum Therapeutics, Inc.

Cash, cash equivalents, and marketable securities of $218.2M as of Dec 31, 2021 (unaudited), sufficient into 2024.
First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; initial data expected Q2 2022.
IND submitted for FTX-6058 to start Phase 1b in select hemoglobinopathies (beta-thalassemia) in Q2 2022.
Update on losmapimod Phase 3 plan for FSHD expected in Q1 2022; no new data yet.
Kate Haviland appointed Chair of board; Mark Levin resigns effective April 18, 2022 (no disagreement).

item 2.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kate Haviland

Chair

FULC · Fulcrum Therapeutics, Inc.

Effective: 2022-01-10
Filed: January 10, 2022, 6:59 PM ET

On January 10, 2022, the Company announced that Kate Haviland has been named Chair of the Board.

Departed

Mark Levin

Executive Chairman

FULC · Fulcrum Therapeutics, Inc.

Effective: 2022-04-18
Successor: Kate Haviland
Filed: January 10, 2022, 6:59 PM ET

On January 5, 2022, Mark Levin notified the Company of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective April 18, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kate Haviland was named as Chair at Fulcrum Therapeutics, Inc..

Action: named
Role: Chair

Exact text from the filing

On January 10, 2022, the Company announced that Kate Haviland has been named Chair of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Levin resigned as Executive Chairman at Fulcrum Therapeutics, Inc..

Action: resigned
Role: Executive Chairman

Exact text from the filing

On January 5, 2022, Mark Levin notified the Company of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective April 18, 2022.

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-005038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.